<DOC>
	<DOCNO>NCT01912443</DOCNO>
	<brief_summary>To assess safety profile bevacizumab combination chemotherapy treatment metastatic colorectal cancer</brief_summary>
	<brief_title>Safety Study Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This multi-centre , observational , non-interventional study . Patients metastatic colorectal cancer eligible Bevacizumab combination chemotherapy treatment enrol trial .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>histologically confirm metastatic colorectal cancer patient metastatic colorectal cancer eligible Bevacizumab combination chemotherapy treatment Written inform consent Unlimited line treatment ( firstline second line limit ) Patients eligible Bevacizumab treatment accord locally approve Bevacizumab China package insert exclude . The following patient eligible Bevacizumab treatment accord local Bevacizumab China package insert : Recent history serious hemorrhage hemoptysis ≥1/2 teaspoon red blood Proteinuria baseline : Patients discover ≥ 2 gram proteinuria/24 hour * The measurement 24hour proteinuria level recommend patient moderate high proteinuria risk indicate clinical judgement . The treatment bevacizumab delay proteinuria ≥2g/24 hour . Major surgical procedure within 28 day prior treatment initiation , fully heal wound Pregnant lactate woman Excluding patient know allergic bevacizumab excipients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>